Issue link: https://viewer.e-digitaledition.com/i/140434
Exposing an Elusive Virus THE MOST COMMON INTRAUTERINE VIRAL INFECTION IN THE UNITED STATES, CYTOMEGALOVIRUS (CMV) IS RESPONSIBLE FOR MORE DEATHS AND LONG-TERM PROBLEMS IN CHILDREN THAN DOWN SYNDROME, FETAL ALCOHOL SYNDROME AND NEURAL TUBE DEFECTS. A BREAKTHROUGH IN THE UNDERSTANDING OF HOW CMV THWARTS NORMAL IMMUNE SYSTEM RESPONSE IS A STEP FORWARD IN THE DEVELOPMENT OF A VACCINE. IN A PA P E R R E C E N T LY published in Cell Host & Microbe, researchers from the La Jolla Institute for Allergy and Immunology and Cardiff University identified the mechanism that allows CMV to evade detection by the immune system. In the study, researchers found that a CMV gene (UL141) blocks two TNF-related apoptosis-inducing ligand (TRAIL) death receptors (DRs). By interfering with these immune pathways, CMV inhibits TRAIL's ability to selectively kill infected cells. The TR AIL protein is normally able to induce death, or apoptosis, in targeted cells by binding to certain DRs, primarily in tumor cells. For this reason, TRAIL has been the focus of anti-cancer therapeutics since the mid-1990s. The importance of TRAIL and its receptors in regulating antiviral immune defenses is only recently becoming more widely known. "Among scientists who study CMV, it is well-known as a 'clever' virus that has evolved a number of strategies to trick the immune system," says study author Chris A. Benedict, PhD, Associate Professor, Division of Immune Regulation at La Jolla Institute. "The novelty and importance of our work is the discovery that one of these strategies is to target the TRAIL DRs." CMV Vaccine Presents Challenges Currently under investigation, the development of a CMV vaccine may be more complex than conventional attenuated or killed virus, as an antibody-only approach may not provide sufficient protection from congenital infection. "I believe strongly that inducing robust cellular immune responses in combination with good antibody responses will be critical to the success of a CMV vaccine," says Benedict. "So, this is where our discovery fits into the picture — I propose that a strategy that boosts the contribution of TRAILmediated cellular immunity, and/or commensurately inhibits the ability of CMV UL141 to block TRAIL DR signaling, will yield a better vaccine." I TH E I M PAC T O F C Y TO M EGALOVI RUS I N FEC TIO N CMV IS A herpesvirus transmitted through direct contact with body fluids such as semen, saliva, urine and breast milk, sexual contact, or through transplanted organs or blood transfusions. In healthy adults and children, CMV normally causes few or no symptoms following initial infection. The virus becomes latent, residing in the body without causing clinical illness, though the immune system must constantly work to suppress replication and reactivation. When transmitted to a child in the womb, CMV can damage the fetus as well as cause significant problems after birth. Each year in the United States, about 30,000 children are born with CMV infection. About 5,000 of these children suffer permanent brain damage, developmental disabilities, cerebral palsy or vision loss. MDNEWS.COM I MD NEWS Eastern Pennsylvania/NW New Jersey | 21

